new matching service has launched for scientists working in the therapeutic area of the central nervous system (CNS) who are ready to move their discoveries from the bench to trials, but have no idea where to turn when it comes to nding and choosing a CRO or lab that knows their therapeutic area well. The Alzheimer’s Drug Discovery Foundation (ADDF) and Science Exchange, which connects scientists with CROs across many therapeutic areas, have united to create the CNS-centric ADDF ACCESS matching service, launching what’s thought to be the first such service tailored to a specific therapeutic area.
Chesapeake IRB, an independent IRB providing study review services across North America, has acquired MaGil IRB and the Institutional Biosafety Corporation, (IBC) both based out of Rockville, Maryland. These acquisitions are merely the most recent for Chesapeake, who has taken on ve AAHRPP- accredited IRBs since 2013, including Compass IRB last year.
To read the full articles for this issue of The CenterWatch Weekly, please click here for subscription information.
